We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

9 hedge funds and large institutions have $763K invested in MAIA Biotechnology in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2.11% more ownership

Funds ownership: 0% → 2.11% (+2.1%)

Holders
9
Holders Change
+9
Holders Change %
–
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynwood Capital Management
Ontario, Canada
+$845K
2
Millennium Management
Millennium Management
New York
+$50K
3
Jane Street
Jane Street
New York
+$43.2K
4
UBS Group
UBS Group
Switzerland
+$19.4K
5
BlackRock
BlackRock
New York
+$15.1K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynwood Capital Management
Ontario, Canada
$659K +$845K +199,785 New
Millennium Management
2
Millennium Management
New York
$39K +$50K +11,811 New
Jane Street
3
Jane Street
New York
$34K +$43.2K +10,210 New
UBS Group
4
UBS Group
Switzerland
$15K +$19.4K +4,588 New
BlackRock
5
BlackRock
New York
$12K +$15.1K +3,572 New
OIA
6
Optimum Investment Advisors
Illinois
$3K +$4.23K +1,000 New
TRCT
7
Tower Research Capital (TRC)
New York
$1K +$1.32K +311 New
Wells Fargo
8
Wells Fargo
California
– +$59 +14 New
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
– +$93 +22 New

MAIA Hedge Fund Activity: Q3 2022 in Review

9 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q3 2022, worth a combined $763K.

Buyers outnumbered sellers: 9 funds opened new MAIA positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Lynwood Capital Management, opening a new position worth an estimated $845K.

  • 9 institutional investors held MAIA Biotechnology (MAIA) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $763K of MAIA Biotechnology stock for Q3 2022.
  • 9 funds opened new MAIA Biotechnology positions in Q3 2022 and 0 closed out, a net change of +9 holders.
  • The largest MAIA Biotechnology buyer in Q3 2022 was Lynwood Capital Management, an estimated $845K added.

Based on aggregated 13F filings for Q3 2022.